Pedras and To

# Interrogation of biosynthetic pathways of the cruciferous phytoalexins nasturlexins with isotopically labelled compounds<sup>1</sup>

M. Soledade C. Pedras\* and Q. Huy To

Department of Chemistry, University of Saskatchewan, 110 Science Place, Saskatoon, SK, S7N 5C9, Canada

\*Corresponding author: E-mail: s.pedras@usask.ca; telephone: 1-306-966-4772; fax: 1-306-966-4730

<sup>&</sup>lt;sup>1</sup> Electronic supplementary information (ESI) available: tables of isotope incorporation data for compounds **18a**, **20a**, **21a**, **5a** and Phe; synthesis of new compounds **18a**, **21a**, **26c**, incorporation schemes with ESI-HR-MS data and ESI spectra; references; <sup>1</sup>H and <sup>13</sup>C NMR spectra of new compounds.

## **Table of contents**

TABLE OF CONTENTS	2
RESULTS	3
Incorporation tables of compounds 18a, 20a, 21a, 5a and Ph	3
EXPERIMENTAL	5
Synthesis of new compounds	5
[2,3,4,5,6,7,8-D <sub>7</sub> ]-( <i>E</i> )-Styryl glucosinolate (18a)	5
[D <sub>3</sub> CS]Methyl [2,3,4,5,6-D <sub>5</sub> ]-(2-hydroxy-2-phenylethyl)dithiocarbamate (21a)	7
[D₃CS]Dihydronasturlexin D (26c)	7
ESI-MS SPECTRA OF INCORPORATION EXPERIMENTS IN UPLAND CRESS (BARBAREA VERNA)	9
Incorporation of [2,3,4,5,6-D₅]gluconasturtiin (8a)	9
Incorporation of [2,4,6-D <sub>3</sub> , <sup>15</sup> N]-3-hydroxygluconasturtiin (9a)	10
Incorporation of [2,3,4,5,6-D <sub>5</sub> ]phenylethyl isothiocyanate (19a)	11
Incorporation of [2,4,6-D <sub>3</sub> , <sup>15</sup> N]-3-hydroxyphenylethyl isothiocyanate (24a)	13
Incorporation of [2,3,4,5,6-D₅]nasturlexin A (1a)	14
Incorporation of [D <sub>3</sub> CS, 2,4,6-D <sub>3</sub> , <sup>15</sup> N]-3-hydroxynasturlexin A (25b)	15
Incorporation of methyl [2,3,4,5,6-D <sub>5</sub> ]-( <i>E</i> )-styryl dithiocarbamate (22a)	
Incorporation of [2,3,4,5,6-D₅]dihydronasturlexin C (23a)	17
Incorporation of [D <sub>3</sub> CS]dihydronasturlexin D (26c)	19
Incorporation of [2,3,4,5,6-D₅]nasturlexin C (11a)	19
ESI-MS SPECTRA OF INCORPORATION EXPERIMENTS IN WATERCRESS (NASTURTIUM OFFICINALE)	20
Incorporation of [D <sub>3</sub> CS 4,5,6,7-D <sub>4</sub> ]brassinin (5a)	
Incorporation of [2,3,4,5,6-D₅]gluconasturtiin (8a)	21
REFERENCES	22
NMR SPECTRA OF NEW COMPOUNDS 18A, 21, 21A,26 AND 26A	22

#### Results

#### Isotope incorporation tables of compounds 18a, 20a, 21a, 5a and Phe

**Table S1.** Metabolism of  $[2,3,4,5,6,7,8-D_7]$ -(*E*)-styryl glucosinolate (**18a**) in elicited and non-elicited leaves of upland cress plants (*Barbarea verna*).

	Elicited leaves	Non-elicited leaves		
Metabolites detected in leaf extracts	% of Deuterium (Conc., $\mu$ mol/100 g) <sup>a</sup>	% Deuterium (Conc., μmol/100 g) <sup>a</sup>		
[2,3,4,5,6,7,8-D <sub>7</sub> ]-( <i>E</i> )-styryl glucosinolate ( <b>18a</b> )	ca. 99 <sup>b</sup> (156 ± 40)	ca. 99% <sup>b</sup> (157 ± 54)		
Gluconasturtiin (8)	NI <sup>c</sup> (2,819 ± 507)	NI <sup>c</sup> (6,171 ± 334)		
Dihydronasturlexin C (23)	NI <sup>c</sup> (≤ 0.3)	NI <sup>c</sup> (ND) <sup>d</sup>		
Nasturlexin C (11)	$NI^{c}$ (16 ± 5)	NI <sup>c</sup> (ND) <sup>d</sup>		
Nasturlexin D (13)	$NI^{c}(28 \pm 10)$	NI <sup>c</sup> (ND) <sup>d</sup>		

<sup>a</sup> Conc. = total concentration of non-labelled and labelled metabolites ( $\mu$ mol/100 g of fresh tissue, quantified by HPLC-DAD); values represent the mean and standard deviation of two independent experiments conducted in triplicate.

<sup>b</sup> Isotope incorporations calculated from HPLC-ESI-MS (peak intensities in negative mode); % of incorporation = { $[M - 1 + n]^{-}/([M - 1]^{-} + [M - 1 + n]^{-})$  × 100 where n = number of D atoms; values represent the mean and standard deviation of two independent experiments conducted in triplicate.

<sup>c</sup> NI = no incorporation means  $D\% \le 0.1$ , ESI-MS.

 $^{d}$  ND = not detected (HPLC-DAD).

**Table S2.** Metabolism of  $[2,3,4,5,6-D_5]$ -(E,Z)-styryl isothiocyanate (**20a**) in elicited leaves of upland cress plants (*Barbarea verna*).

Metabolites detected in leaf extracts	% of Deuterium (Conc., $\mu$ mol/100 g) <sup>a</sup>			
$[2,3,4,5,6-D_5]-(E,Z)-$ Styryl isothiocyanate ( <b>20a</b> )	NI <sup>b</sup> (ND) <sup>c</sup>			
Dihydronasturlexin C (23)	NI <sup>b</sup> (11 ± 13)			
Nasturlexin C (11)	NI <sup>b</sup> (12 ± 9)			
Nasturlexin D (13)	NI <sup>b</sup> (3 ± 2)			

<sup>a</sup> Conc. = total concentration of non-labelled and labelled metabolites ( $\mu$ mol/100 g of fresh tissue, quantified by HPLC-

DAD); values represent the mean and standard deviation of two independent experiments conducted in triplicate.

<sup>b</sup> NI = no incorporation means  $D\% \le 0.1$ , ESI-MS.

<sup>c</sup> ND = not detected (HPLC-DAD).

**Table S3.** Metabolism of  $[D_3CS]$  methyl (2-hydroxy-2- $[2,3,4,5,6-D_5]$  phenylethyl) dithiocarbamate (**21a**) in elicited leaves of upland cress plants (*Barbarea verna*).

Metabolites detected in leaf extracts	% of Deuterium (Conc., μmol/100 g) <sup>a</sup>		
[D <sub>3</sub> CS]methyl (2-hydroxy-2-[2,3,4,5,6-D <sub>5</sub> ]phenylethyl) dithiocarbamate ( <b>21a</b> )	NI <sup>b</sup> (ND) <sup>c</sup>		
Dihydronasturlexin C (23)	NI <sup>b</sup> (37 ± 8)		
Nasturlexin C (11)	$NI^{b}(52 \pm 28)$		
Nasturlexin D (13)	NI <sup>b</sup> (99 ± 25)		

<sup>a</sup> Conc. = total concentration of non-labelled and labelled metabolites ( $\mu$ mol/100 g of fresh tissue, quantified by HPLC-DAD); values represent the mean and standard deviation of two independent experiments conducted in triplicate.

<sup>b</sup> NI = no incorporation means  $D\% \le 0.1$ , ESI-MS.

<sup>c</sup> ND = not detected (HPLC-DAD).

**Table S4.** Metabolism of  $[2,3,4,5,6-D_5]$  phenylalanine in elicited leaves of watercress (*Nasturtium officinale*).

Metabolites detected in leaf extracts	% of Deuterium (Conc., μmol/100 g) <sup>a</sup>
[2,3,4,5,6-D <sub>5</sub> ]Phenylalanine	$52 \pm 14^{\text{b}} (369 \pm 147)$
Gluconasturtiin (8)	NI <sup>c</sup> (467 ± 132)
Nasturlexin B (2)	$NI^{c} (8 \pm 6)$
[2,3,5,6-D <sub>4</sub> ]Tridentatol C ( <b>3</b> )	NI <sup>c</sup> (≤2)
Cyclonasturlexin (4)	NI <sup>c</sup> (≤5)

<sup>a</sup> Conc. = total concentration of natural abundance and labelled metabolites (nmol/g of fresh tissue, quantified by HPLC-DAD); values represent the mean and standard deviation of triplicate samples.

<sup>b</sup> Isotope incorporations calculated from HPLC-ESI-MS (peak intensities in positive mode); % of incorporation =  $\{[M + 1 + n]^+/([M + 1]^+ + [M + 1 + n]^+)\} \times 100$ , where n = number of D atoms; values represent the mean and standard deviation of triplicate samples.

<sup>c</sup> NI = no incorporation means  $D\% \le 0.1$ , ESI-MS.

	Elicited leaves	Non-elicited leaves		
Metabolites	% of Deuterium	% of Deuterium		
	(Conc., µmol/100 g) <sup>a</sup>	(Conc., µmol/100 g) <sup>a</sup>		
[D <sub>3</sub> CS, 4,5,6,7- D <sub>4</sub> ]Brassinin ( <b>5</b> a)	$\geq 97^{\rm b}~(9\pm6)$	$\geq 97^{\rm b} \left( 39 \pm 8 \right)$		
$[D_3SC, 5, 6, 7-D_3]$ Cyclonasturlexin ( <b>4b</b> )	$62 \pm 17^{b} (74 \pm 26)$	$96 \pm 3^{\rm b} (\le 5)$		

**Table S5.** Metabolism of  $[D_3C-S 4,5,6,7-D_4]$  brassinin (**5a**) in elicited and non-elicited leaves of watercress (*Nasturtium officinale*).

<sup>a</sup> Conc. = total concentration of non-labelled and labelled metabolites (nmol/g of fresh tissue, quantified by HPLC-DAD). Values represent the mean and standard deviation of triplicate samples.

<sup>b</sup> Isotope incorporations calculated from HPLC-ESI-MS (peak intensities in positive mode); % of incorporation = { $[M + 1 + n]^+/([M + 1]^+ + [M + 1 + n]^+)$ } × 100, where n = number of D atoms, values represent the mean and S.D. of triplicate samples.

## **Experimental**

#### Synthesis of new compounds

#### [2,3,4,5,6,7,8-D<sub>7</sub>]-(*E*)-Styryl glucosinolate (18a)



**Scheme S1.** Synthesis of [2,3,4,5,6,7,8-D<sub>7</sub>]-(*E*)-styryl glucosinolate (**18a**).

A suspension of LiAlH<sub>4</sub> in dry THF (0.75 mL) was added dropwise to a solution of *trans*-[2,3,4,5,6,7,8-D<sub>7</sub>]cinnamic acid (**42a**, 98%D, 150 mg, 0.97 mmol) in dry THF (0.75 mL) at 0 °C.<sup>1</sup>After stirring at rt for 30 min, the reaction mixture was added dropwise to a vigorously stirred suspension of PCC (420 mg,

1.94 mmol) in dry DCM (2.5 mL). The mixture was stirred for 2 h and filtered through celite. The filtrate was concentrated and fractionated by FCC (EtOAc-hexane, 1:9) to give *trans*-[2,3,4,5,6,7,8-D<sub>7</sub>]cinnamaldehyde (**43a**) (55 mg, 0.40 mmol, 41%). A solution of NH<sub>2</sub>OH·HCl (27mg, 0.38 mmol) and NaOAc (31 mg, 0.38 mmol) in H<sub>2</sub>O (1.0 mL) was added to a solution aldehyde **43a** (35 mg, 0.25 mmol) in EtOH (1.0 mL) at rt. After stirring for 1 h, the mixture was concentrated, diluted with H<sub>2</sub>O and extracted with EtOAc. The organic extract was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give oxime **44a** (39 mg, 0.25 mmol) and pyridine (0.10 mL) in DCM (1.0 mL) at 0 °C. After stirring at rt for 30 min, a solution of 1- $\beta$ -D-thioglucose tetraacetate (82 mg, 0.22 mmol) and Et<sub>3</sub>N (105  $\mu$ L, 0.75 mmol) in DCM (1.0 mL) was added and stirring was continued for 4 h. The mixture was diluted with 1 M H<sub>2</sub>SO<sub>4</sub> and extracted with DCM. The organic extract was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and separated by FCC (EtOAc-hexane, 1:1) to give thiohydroximate **45a** (101 mg, 0.20 mmol, 91%) as a yellowish solid.

Compound **45a**: <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  8.06 (1H, s), 5.22 (1H, t, *J* = 9.0 Hz), 5.15-5.08 (2H, m), 5.05 (1H, d, *J* = 10.0 Hz), 4.25 (1H, dd, *J* = 12.0, 5.5 Hz), 4.12 (1H, dd, *J* = 12.0, 2.0 Hz), 3.74-3.72 (1H, m), 2.06 (3H, s), 2.02 (3H, s), 2.02 (3H, s), 2.00 (3H, s). HR-ESI-MS *m*/*z* [M + H]<sup>+</sup>: calc. for C<sub>23</sub>H<sub>21</sub><sup>2</sup>H<sub>7</sub>NO<sub>10</sub>S: 517.1868, found 517.1880 (28%), 331.10 (100%).

 $PySO_3$  (80 mg, 0.60 mmol) was added to a solution of thiohydroximate **45a** (64 mg, 0.12 mmol) in dry DCM (3.0 mL) and the mixture was stirred at 40 °C for 18 h. Solvent was concentrated, H<sub>2</sub>O was added, and the mixture was extracted with MeOH-CHCl<sub>3</sub> (1:4). The organic extract was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and separated by FCC (MeOH-DCM, 1:9) to give compound **46a** (64 mg, 0.11 mmol, 89%) as a solid.

Compound **46a**: <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD):  $\delta$  5.40-5.34 (2H, m), 5.09-5.04 (2H, m), 4.25 (1H, dd, *J* = 12.5, 6.0 Hz), 4.12 (1H, dd, *J* = 12.5, 2.0 Hz), 4.02-3.98 (1H, m), 2.04 (3H, s), 2.01 (3H, s), 1.97 (3H, s), 1.92 (3H, s). HR-ESI-MS *m*/*z* [M-H]<sup>-</sup>: calc. for C<sub>23</sub>H<sub>19</sub><sup>2</sup>H<sub>7</sub>NO<sub>13</sub>S<sub>2</sub>: 595.1279, found 595.1301 (100%). K<sub>2</sub>CO<sub>3</sub> (28 mg, 0.20 mmol) was added to a solution of **46a** (40 mg, 0.067 mmol) in MeOH (2.0 mL) at rt. After stirring for 1 h, the mixture was neutralized with acetic acid (ca. 1 drop) and filtered. The filtrate was concentrated to give [2,3,4,5,6,7,8-D<sub>7</sub>]-(*E*)-styryl glucosinolate (**18a**) in a quantitative yield. The spectroscopic data of the non-labelled compound **18** was in agreement with reported literature.<sup>2</sup>

Compound **18a**: HPLC  $t_{\rm R} = 12.1$  min (method B). <sup>1</sup>H NMR (500 MHz, D<sub>2</sub>O):  $\delta$  5.04 (1H, d, J = 9.5 Hz), 3.88 (1H, dd, J = 12.5, 2.0 Hz), 3.70 (1H, dd, J = 12.5, 5.0 Hz), 3.56-3.44 (4H, m). <sup>13</sup>C NMR (125 MHz, D<sub>2</sub>O):  $\delta$  161.1, 134.6, 82.7, 80.5, 77.1, 72.0, 69.2, 60.6. HR-ESI-MS m/z [M-K]<sup>-</sup>: calc. for C<sub>15</sub>H<sub>11</sub><sup>2</sup>H<sub>7</sub>NO<sub>9</sub>S<sub>2</sub>: 427.0857, found 427.0868 (100%). UV (HPLC, CH<sub>3</sub>CN–H<sub>2</sub>O)  $\lambda_{max}$  (nm): 220, 280.

#### [D<sub>3</sub>CS]Methyl [2,3,4,5,6-D<sub>5</sub>]-(2-hydroxy-2-phenylethyl)dithiocarbamate (21a)



Scheme S2. Synthesis of [D<sub>3</sub>CS]Methyl [2,3,4,5,6-D<sub>5</sub>]-(2-hydroxy-2-phenylethyl) dithiocarbamate (21a)

Compound **47a** was synthesized as previously reported.<sup>3</sup> CS<sub>2</sub> (9  $\mu$ L, 0.15 mmol) was added to a solution of **47a** (20 mg, 0.14 mmol) in pyridine (0.50 mL) at 0 °C, followed by Et<sub>3</sub>N (60  $\mu$ L, 0.42 mmol). After stirring for 15 min, CD<sub>3</sub>I (9  $\mu$ L, 0.15 mmol) was added and stirring was continued for 30 min. The mixture was diluted with EtOAc and washed with 1 M H<sub>2</sub>SO<sub>4</sub>. The organic extract was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give compound **21a** (30 mg, 0.13 mmol, 93%, D ≥ 99%, determined by HR-FD-MS).

Compound **21a**: HPLC  $t_{\rm R} = 12.4$  min (method A). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.48 (1H, br), 5.05 (1H, dd, J = 8.5, 3.5 Hz), 4.36-4.32 (1H, m), 3.68-3.63 (1H, m), 2.52 (1H, br), and a rotamer at 8.15 (br), 4.98 (br), 3.78 (br), 3.54 (br). HR-FD-MS *m*/*z*: calc. for C<sub>10</sub>H<sub>5</sub><sup>2</sup>H<sub>8</sub>NOS<sub>2</sub>: 235.0941, found 235.0934. UV (HPLC, CH<sub>3</sub>CN – H<sub>2</sub>O)  $\lambda_{\rm max}$  (nm): 250, 270.

Compound **21**: HPLC  $t_R = 12.4 \text{ min}$  (method A). <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.56 (1H, br), 7.40-7.31 (5H, m), 5.04 (1H, dd, J = 9.0, 3.5 Hz), 4.34-4.30 (1H, m), 3.67-3.63 (1H, m), 2.67 (1H, s), 2.63 (3H, s), and a rotamer at 8.23 (br), 4.96 (br), 3.77 (br), 3.53 (br). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>):  $\delta$  200.4, 141.2, 128.9, 128.5, 126.0, 72.5, 53.9, 18.5. HR-FD-MS *m*/*z*: calc. for C<sub>10</sub>H<sub>13</sub>NOS<sub>2</sub>: 227.0439, found 227.0441. UV (HPLC, CH<sub>3</sub>CN – H<sub>2</sub>O)  $\lambda_{max}$  (nm): 250, 270.

#### [D<sub>3</sub>CS]Dihydronasturlexin D (26c)



Scheme S3. Synthesis of [D<sub>3</sub>CS]dihydronasturlexin D (26c)

A solution of SOCl<sub>2</sub> (362  $\mu$ L, 5.0 mmol) and DMF (10  $\mu$ L) in CHCl<sub>3</sub> (1.0 mL) was added dropwise to a suspension of norphenylephrine hydrochloride (**48**) (95 mg, 0.50 mmol) in CHCl<sub>3</sub> (2.0 mL) at rt.<sup>3</sup> After stirring for 24 h, solvent was removed and the mixture was washed with Et<sub>2</sub>O and concentrated to give compound **49**. CS<sub>2</sub> (60  $\mu$ L, 1.0 mmol) was added to a suspension of **49** in CHCl<sub>3</sub> (3.0 mL) at rt, followed by Et<sub>3</sub>N (210  $\mu$ L, 1.5 mmol). After stirring for 15 min, CD<sub>3</sub>I (60  $\mu$ L, 1.0 mmol) was added and stirring was continued for 1 h. H<sub>2</sub>O was added and the mixture was extracted with CHCl<sub>3</sub>. The organic extract was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated and separated by FCC (EtOAc-hexane, 1:3) to give compound [D<sub>3</sub>CS]Dihydronasturlexin D (**26c**) (52 mg, 0.23 mmol, 46%; D ≥ 99%, determined by HR-FD-MS) as a solid.

Compound **26c**: HPLC  $t_{\rm R} = 11.5$  min (method A). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>CN):  $\delta$  7.15 (1H, t, J = 8.0 Hz), 6.79 (1H, d, J = 8.0 Hz), 6.75 (1H, t, J = 2.0 Hz), 6.72-6.70 (1H, m), 5.08 (1H, dd, J = 8.5, 5.0 Hz), 4.44 (1H, dd, J = 15.0, 8.5 Hz), 4.29 (1H, dd, J = 15.0, 5.0 Hz). HR-FD-MS m/z [M]<sup>+</sup> calc. for C<sub>10</sub>H<sub>8</sub><sup>2</sup>H<sub>3</sub>NOS<sub>2</sub>: 228.0470, found 228.0461 (100%). UV (HPLC, CH<sub>3</sub>CN-H<sub>2</sub>O)  $\lambda_{max}$  (nm): 220, 280. Compound **26**: HPLC  $t_{\rm R} = 11.5$  min (method A). <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>CN):  $\delta$  7.16 (1H, t, J = 8.0 Hz), 6.79 (1H, d, J = 8.0 Hz), 6.75 (1H, s), 6.72-6.70 (1H, m), 5.09 (1H, dd, J = 8.5, 5.5 Hz), 4.45 (1H, dd, J = 15.0, 8.5 Hz), 4.30 (1H, dd, J = 15.0, 5.0 Hz), 2.55 (3H, s). <sup>13</sup>C NMR (150 MHz, CD<sub>3</sub>CN):  $\delta$  166.1, 158.6, 144.8, 131.4, 119.7, 116.1, 115.0, 73.0, 57.4, 16.0. HR-FD-MS m/z [M]<sup>+</sup> calc. for C<sub>10</sub>H<sub>11</sub>NOS<sub>2</sub>: 225.0282, found 225.0277 (100%). UV (HPLC, CH<sub>3</sub>CN-H<sub>2</sub>O)  $\lambda_{max}$  (nm): 220, 280.

## ESI-MS spectra of incorporation experiments in upland cress (Barbarea verna)

Incorporation of [2,3,4,5,6-D<sub>5</sub>]gluconasturtiin (8a)



 $[2,3,4,5,6-D_5]$ Nasturlexin C (**11a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>5</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 213.0569, found 213.0578.

 $[2,3,5,6-D_4]$ Nasturlexin D (13b): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0455, found 228.0459.



Figure S1 ESI-MS spectra (positive mode) of nasturlexins C (11/11a) and D (13/13b) in extracts of elicited leaves (A and B) fed with  $[2,3,4,5,6-D_5]$  gluconasturtiin (8a) and control leaves.

### Incorporation of [2,4,6-D<sub>3</sub>,<sup>15</sup>N]-3-hydroxygluconasturtiin (9a)



[2,4,6-D<sub>3</sub>,<sup>15</sup>N]Dihydronasturlexin D (**26a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>9</sub><sup>2</sup>H<sub>3</sub><sup>15</sup>NS<sub>2</sub>, 230.0519, found 230.0512. [2,4,6-D<sub>3</sub>,<sup>15</sup>N]Nasturlexin D (**13a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>3</sub><sup>15</sup>NS<sub>2</sub>: 228.0362, found 228.0355.





Figure S2 ESI-MS spectra (positive mode) of 3-hydroxyphenylethyl isothiocyanate (24/24a), dihydronasturlexin D (26/26a), and nasturlexin D (13/13a) in extracts of elicited leaves (A, B and C) fed with  $[2,4,6-D_3,^{15}N]$ -3-hydroxyphenylethyl glucosinolate (9a) and control leaves.

Incorporation of [2,3,4,5,6-D<sub>5</sub>]phenylethyl isothiocyanate (19a)



 $[2,3,4,5,6-D_5]$ Nasturlexin C (**11a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>5</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 213.0569, found 213.0557.

 $[2,3,5,6-D_4]$ Nasturlexin D (**13b**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0455, found 228.0446.



Figure S3 ESI-MS spectra (positive mode) of dihydronasturlexin C (23/23a), nasturlexins C (11/11a) and D (13/13b) in extracts of elicited leaves (A, B and C) fed with  $[2,3,4,5,6-D_5]$  phenylethyl isothiocyanate (19a) and control leaves.

Incorporation of [2,4,6-D<sub>3</sub>,<sup>15</sup>N]-3-hydroxyphenylethyl isothiocyanate (24a)



 $[2,4,6-D_3,^{15}N]$ Dihydronasturlexin D (**26a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>9</sub><sup>2</sup>H<sub>3</sub><sup>15</sup>NS<sub>2</sub>, 230.0519, found 230.0536.

 $[2,4,6-D_3,^{15}N]$ Nasturlexin D (**13a**): HR-ESI-MS *m*/*z* [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>3</sub><sup>15</sup>NS<sub>2</sub>, 228.0362, found 228.0399.



**Figure S4** ESI-MS spectra (positive mode) of dihydronasturlexin D (26/26a) and nasturlexin D (13/13a) in extracts of elicited leaves (A and B) fed with [2,4,6-D<sub>3</sub>,<sup>15</sup>N]-3-hydroxyphenylethyl isothiocyanate (24a) and control leaves.

## Incorporation of [2,3,4,5,6-D<sub>5</sub>]nasturlexin A (1a)



 $[2,3,4,5,6-D_5]$ Dihydronasturlexin C (**23a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 215.0725, found 215.0737.

 $[2,3,4,5,6-D_5]$ Nasturlexin C (**11a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>5</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 213.0569, found 213.0557.

 $[2,3,5,6-D_4]$ Nasturlexin D (**13b**): HR-ESI-MS *m*/*z* [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0455, found 228.0446.





Figure S5 ESI-MS spectra (positive mode) of dihydronasturlexin C (23/23a), nasturlexins C (11/11a) and D (13/13b) in extracts of elicited leaves (A, B and C) fed with  $[2,3,4,5,6-D_5]$ nasturlexin A (1a) and control leaves.

## Incorporation of [D<sub>3</sub>CS, 2,4,6-D<sub>3</sub>,<sup>15</sup>N]-3-hydroxynasturlexin A (25b)



 $[D_3CS, 2,4,6-D_3,^{15}N]$ Dihydronasturlexin D (**26b**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for  $C_{10}H_6^2H_6^{15}NS_2$ , 233.0707, found 233.0698.

 $[D_3CS, 2,4,6-D_3,^{15}N]$ Nasturlexin D (**13c**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>4</sub><sup>2</sup>H<sub>6</sub><sup>15</sup>NS<sub>2</sub>, 231.0551, found 231.0538.



**Figure S6** ESI-MS spectra (positive mode) of dihydronasturlexin D (**26/26b**) and nasturlexin D (**13/13c**) in extracts of elicited leaves (A and B) fed with  $[D_3CS, 2,4,6-D_3,^{15}N]$ -3-hydroxynasturlexin A (**25b**) and control leaves.

#### Incorporation of methyl [2,3,4,5,6-D<sub>5</sub>]-(*E*)-styryl dithiocarbamate (22a)



 $[2,3,4,5,6-D_5]$ Nasturlexin C (**11a**): GC-FI-MS *m*/*z* [M]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>4</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 212.0490, found 212.0487.



**Figure S7** ESI-MS spectra (positive mode) of nasturlexin C (11/11a) in extracts of elicited leaves (A) fed with methyl  $[2,3,4,5,6-D_5]$ -(*E*)-styryl dithiocarbamate (22a) and control leaves.

Incorporation of [2,3,4,5,6-D<sub>5</sub>]dihydronasturlexin C (23a)



 $[2,3,4,5,6-D_5]$ Nasturlexin C (**11a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>5</sub><sup>2</sup>H<sub>5</sub>NS<sub>2</sub>, 213.0569, found 213.0567.

 $[2,3,4,5,6-D_5]$ Nasturlexin C sulfoxide (**12a**): HR-ESI-MS *m*/*z* [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>5</sub>NOS<sub>2</sub>, 229.0533, found 229.0546.

 $[2,3,5,6-D_4]$ Nasturlexin D (**13b**): HR-ESI-MS *m*/*z* [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0455, found 228.0443.



Figure S8 ESI-MS spectra (positive mode) of nasturlexins C (11/11a), C sulfoxide (12/12a), and D (13/13b) in extracts of elicited leaves (A, B, and C) fed with  $[2,3,4,5,6-D_5]$  dihydronasturlexin C (23a) and control leaves.

#### Incorporation of [D<sub>3</sub>CS]dihydronasturlexin D (26c)



 $[D_3CS]$ Nasturlexin D (13d): HR-ESI-MS m/z  $[M + H]^+$ , calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>3</sub>NOS<sub>2</sub>, 227.0392, found 227.0389.



**Figure S9** ESI-MS spectra (positive mode) of nasturlexin D (13/13d) in extracts of elicited leaves (A) fed with [D<sub>3</sub>CS]dihydronasturlexin D (26c) and control leaves.

#### Incorporation of [2,3,4,5,6-D<sub>5</sub>]nasturlexin C (11a)



 $[2,3,4,5,6-D_5]$ Nasturlexin C sulfoxide (**12a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>7</sub><sup>2</sup>H<sub>5</sub>NOS<sub>2</sub>, 229.0533, found 229.0540.

 $[2,3,5,6-D_4]$ Nasturlexin D (13b): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0455, found 228.0460.



**Figure S10** ESI-MS spectra (positive mode) of nasturlexin C sulfoxide (12/12a) and nasturlexin D (13/13b) in extracts of elicited leaves (A and B) fed with [2,3,4,5,6-D<sub>5</sub>]nasturlexin C (11a) and control leaves.

#### **ESI-MS** spectra of incorporation experiments in watercress (*Nasturtium officinale*)

Incorporation of [D<sub>3</sub>CS 4,5,6,7-D<sub>4</sub>]brassinin (5a)



 $[D_3CS 4,5,6,7-D_4]$ cyclonasturlexin (**4a**): HR-ESI-MS m/z  $[M + H]^+$ , calculated for  $C_{11}H_5^2H_6N_2S_2$ , 241.0735, found 241.0739.



**Figure S11** ESI-MS spectra (positive mode) of cyclonasturlexin (4/4a) in extracts of elicited leaves (A) fed with [D<sub>3</sub>CS 4,5,6,7-D<sub>4</sub>]brassinin (5a) and control leaves.

Incorporation of [2,3,4,5,6-D<sub>5</sub>]gluconasturtiin (8a)



 $[2,3,5,6-D_4]$ Nasturlexin B (2a): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>8</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 230.0606, found 230.0635.

 $[2,3,5,6-D_4]$ Tridentatol C (**3a**): HR-ESI-MS m/z [M + H]<sup>+</sup>, calculated for C<sub>10</sub>H<sub>6</sub><sup>2</sup>H<sub>4</sub>NOS<sub>2</sub>, 228.0449, found 228.0459.



Figure S12 ESI-MS spectra (positive mode) of nasturlexin B (2/2a) and tridentatol C (3/3a) in extracts of elicited leaves (A and B) fed with  $[2,3,4,5,6-D_5]$ gluconasturtiin (8a) and control leaves.

## References

- 1 J. S. Cha, J. H. Chun, J. M. Kim, O. O. Kwon, S. Y. Kwon and J. C. Lee, *Bull. Korean Chem. Soc.*, 1999, **20**, 400–402.
- 2 Q. V Vo, C. Trenerry, S. Rochfort, J. Wadeson, C. Leyton and A. B. Hughes, *Bioorg. Med. Chem.*, 2013, **21**, 5945–5954.
- 3 M. S. C. Pedras and Q. H. To, J. Label. Compd. Radiopharm., 2018, 61, 94–106.

### NMR spectra of new compounds 18a, 21, 21a, 26 and 26a









Compound <b>21</b> - <sup>13</sup> C NMR Spectrum CDCl <sub>3</sub>												26
		128.92	)		₹77.44	72.53						
OH H N SCH <sub>3</sub>					ľ							
	1											
210 200 190 180 170 160 150		130	<b>120</b> 1	 			••••••••••••••••••••••••••••••••••••••	50	40	30	20	maa





Compound <b>26</b> - ${}^{13}C$ NM	R Spectrum	1						29
SCH3 SCH3 CH OH				119.70 118.68 114.95	73.01	57.44	16.03 2.19 2.12	1.88
		<b>50 140</b>	130	120 110 1	00 90 80 7	70 60 {		10 ppm